Glenmark Pharmaceuticals Friday said it has received final approval from the US health regulator for Ezetimibe and Simvastatin tablets, used for treating high levels of cholesterol in the blood.
Citing IQVIA sales data, Glenmark said Vytorin tablets’ market achieved annual sales of approximately USD 92.4 million for the 12-month period ended April 2019. Image source: www.glenmarkpharma.com
